Inverness Broadens Glucose Monitoring Portfolio Via LXN Acquisition
This article was originally published in The Gray Sheet
Executive Summary
Inverness Medical Technology's acquisition of privately held LXN Corp., and with it the InCharge GlucoProtein home test, expands the firm's presence in the Type 2 diabetes market.